Candriam S.C.A. Increases Stock Holdings in Bruker Corporation $BRKR

Candriam S.C.A. lifted its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 23.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 676,424 shares of the medical research company’s stock after buying an additional 128,821 shares during the quarter. Candriam S.C.A.’s holdings in Bruker were worth $24,432,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Los Angeles Capital Management LLC acquired a new stake in Bruker in the fourth quarter valued at approximately $26,000. Allworth Financial LP lifted its position in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the period. Summit Securities Group LLC purchased a new position in shares of Bruker in the fourth quarter valued at $50,000. Finally, Covestor Ltd grew its holdings in Bruker by 304.6% during the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BRKR shares. JPMorgan Chase & Co. lifted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Guggenheim raised their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Citigroup lifted their price target on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Leerink Partners increased their price objective on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Bruker has a consensus rating of “Hold” and a consensus price target of $56.79.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 27.20% of the stock is currently owned by insiders.

Bruker Stock Performance

Shares of NASDAQ:BRKR traded down $0.52 during trading on Friday, reaching $60.06. 1,150,260 shares of the company’s stock traded hands, compared to its average volume of 2,074,879. The stock has a market capitalization of $9.14 billion, a P/E ratio of -250.25, a price-to-earnings-growth ratio of 1.92 and a beta of 1.29. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.54. The company has a 50 day moving average of $52.92 and a 200-day moving average of $45.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio is presently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.